Volpi, S.; Ambroni, M.; Buzzetti, R.; Cimino, G.; Gramegna, A.; Lucanto, M.C.; Ripani, P.; Ros, M.; Salvatore, D.; Spada, E.;
et al. Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study. Int. J. Mol. Sci. 2025, 26, 10513.
https://doi.org/10.3390/ijms262110513
AMA Style
Volpi S, Ambroni M, Buzzetti R, Cimino G, Gramegna A, Lucanto MC, Ripani P, Ros M, Salvatore D, Spada E,
et al. Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study. International Journal of Molecular Sciences. 2025; 26(21):10513.
https://doi.org/10.3390/ijms262110513
Chicago/Turabian Style
Volpi, Sonia, Maura Ambroni, Roberto Buzzetti, Giuseppe Cimino, Andrea Gramegna, Maria Cristina Lucanto, Pietro Ripani, Mirco Ros, Donatello Salvatore, Elena Spada,
and et al. 2025. "Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study" International Journal of Molecular Sciences 26, no. 21: 10513.
https://doi.org/10.3390/ijms262110513
APA Style
Volpi, S., Ambroni, M., Buzzetti, R., Cimino, G., Gramegna, A., Lucanto, M. C., Ripani, P., Ros, M., Salvatore, D., Spada, E., & Braggion, C., on behalf of the Italian SITTMA Study Group.
(2025). Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study. International Journal of Molecular Sciences, 26(21), 10513.
https://doi.org/10.3390/ijms262110513